DUBLIN–(BUSINESS WIRE)–The “Gastrointestinal Drugs Global Market Opportunities And Strategies To 2030, By Type, Distribution Channel, Route Of Administration, Drug Classification, Mode Of Purchase” report has been added to ResearchAndMarkets.com’s offering.
The global gastrointestinal drugs market reached a value of nearly $46,679.8 million in 2020, having increased at a CAGR of 4.9% since 2015. The market is expected to grow from $46,679.8 million in 2020 to $62,191.6 million in 2025 at a rate of 5.9%. The market is then expected to grow at a CAGR of 5.1% from 2025 and reach $79,871.1 million in 2030.
Growth in the historic period in the gastrointestinal drugs market resulted from changes in lifestyles, strong economic growth in emerging markets, increase in pharmaceutical R&D expenditure, increase in insurance coverage, aging population trends, and increased healthcare expenditure. The market was restrained by patent expiration of drugs, challenges due to regulatory changes, low healthcare access, and increased preference for biological treatments.
Going forward, increasing prevalence of gastrointestinal diseases, new methods for drug discovery, new methods for drug delivery and monitoring, rise in healthcare expenditure, and increasing geriatric population will drive the growth in the gastrointestinal drugs market. Factors that could hinder the growth of the market in the future include high costs of drugs, rising popularity of alternative therapies, and the coronavirus pandemic.
The gastrointestinal drugs market is segmented by type into antacids, antiulcerants, antiemetics and antinauseants, antidiarrheals, and others. The antiulcerants were the largest segment of the gastrointestinal drugs market segmented by type, accounting for 51.2% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the gastrointestinal drugs market segmented by type, at a CAGR of 6.9% during 2020-2025.
The gastrointestinal drugs market is segmented by distribution channel into hospital pharmacies, retail pharmacies/ drug stores and others. The retail pharmacies/ drug stores were the largest segment of the gastrointestinal drugs market segmented by distribution channel, accounting for 52.5% of the total in 2020. Going forward, the retail pharmacies/ drug stores segment is expected to be the fastest growing segment in the gastrointestinal drugs market segmented by distribution channel, at a CAGR of 9.6% during 2020-2025.
The gastrointestinal drugs market is segmented by route of administration into oral and parenteral. The parenteral was the largest segment of the gastrointestinal drugs market segmented by route of administration, accounting for 59.5% of the total in 2020. Going forward, the oral segment is expected to be the fastest growing segment in the gastrointestinal drugs market segmented by route of administration, at a CAGR of 7.0% during 2020-2025.
North America was the largest region in the gastrointestinal drugs market, accounting for 47.6% of the total in 2020. It was followed by the Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the gastrointestinal drugs market will be South America and Africa where growth will be at CAGRs of 9.6% and 8.3% respectively during 2020-2025. These will be followed by Middle East and Asia Pacific, where the markets are expected to register CAGRs of 7.7% and 6.7% respectively during 2020-2025.
The top opportunities in the gastrointestinal drugs market segmented by type will arise in the antiulcerants segment, which will gain $7,123.0 million of global annual sales by 2025. The top opportunities in the gastrointestinal drugs market segmented by distribution channel will arise in the retail pharmacies segment, which will gain $14,178.1 million of global annual sales by 2025.
The top opportunities in the gastrointestinal drugs market segmented by route of administration will arise in the parenteral segment, which will gain $7,941.0 million of global annual sales by 2025. The top opportunities in the gastrointestinal drugs market segmented by drug classification will arise in the branded segment, which will gain $8,974.5 million of global annual sales by 2025. The top opportunities in the gastrointestinal drugs market segmented by mode of purchase will arise in the prescription segment, which will gain $11,999.5 million of global annual sales by 2025. The gastrointestinal drugs market size will gain the most in the USA at $5,756.2 million.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider gastrointestinal drugs market; and compares it with other markets.
Markets Covered:
- By Type: Antacids; Antiulcerants; Antiemetics And Antinauseants; Antidiarrheals; Others
- By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
- By Route Of Administration: Oral; Parenteral; Others
- By Drug Classification: Branded Drugs; Generic Drugs
- By Mode Of Purchase: Prescription Drugs; Over The Counter Drugs
Companies Mentioned
- Takeda Pharmaceutical
- AbbVie
- Johnson & Johnson
- Bausch Health
- AstraZeneca Plc
- Sanofi
- Bayer AG
- Pfizer Inc.
- GlaxoSmithKline plc
- The Procter & Gamble Company
For more information about this report visit https://www.researchandmarkets.com/r/tt81kw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900